Trivehexin (RAD 301) radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrin has received an Orphan Drug Designation by the FDA

The Company now holds two FDA Orphan Drug Designations, along with the LRRC15 antibody DUNP19, for the treatment of patients with osteosarcoma

Additionally, Radiopharm and TRIMT GmbH have signed an exclusive licensing agreement for the development and commercialization of RAD 301 in the US, Australia, China, Hong Kong, and Japan